



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Art Unit	: 1654	Customer No.: 035811
Examiner	: Hemant Khanna	
Serial No.	: 10/528,320	
Filed	: March 17, 2005	
Inventors	: Pascal Dumy	Docket No.: 1383-PCT-US-02
	: MariChristine Favrot	
	: Didier Boturyn	Confirmation No.: 4534
	: Jean-Luc Coll	
Title	: SYNTHESIS AND CHARACTERIZATION	
	: OF NOVEL SYSTEMS FOR GUIDANCE	
	: AND VECTORIZATION OF MOLECULES	
	: OF THERAPEUTIC INTEREST TOWARDS	
	: TARGET CELLS	

Dated: August 11, 2006

RESPONSE

Mail Stop Amendment

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

This is submitted in response to the Official Action dated June 27, 2006.

The Applicants note the restriction requirement dividing the application into Group I including Claims 36-59; Group II including Claims 60-66; and Group III including Claims 67-68.

The Applicants elect Group II including Claims 60-66 for immediate prosecution. This election is made with traverse for the reasons set forth below.

The Applicants respectfully submit that although the claims in Groups I and III may be withdrawn from immediate prosecution, the Applicants specifically reserve their right to pursue those claims in this application or one or more divisional applications.

The Applicants note the requirement for the election of species. The Applicants therefore elect the homodetic cyclopeptide with the guiding element c[RGDfK] on one face and a detection agent or a cytotoxic biomolecule on the other face. The Applicants note that Claim 62 reads on this

election. This election is also made with traverse.

The Applicants acknowledge the Examiner's comments that allege that the inventions listed as Group I and III do not relate to a single general inventive concept under PCT Rule 13.1 because they lack the same or corresponding special technical features such as a shared technical feature (the $\alpha\beta3$ integrin inhibitor, cyclo (RGDfK) which is allegedly anticipated by Liu. The Applicants also note the comments with respect to the species not relating to a single general inventive concept under PCT Rule 13.1 because the species lack the same or corresponding technical features which is the same as set forth above with respect to the restriction requirement.

The Applicants respectfully submit that all of the claims and species fall within the unity of invention requirements of the PCT rules inasmuch as the common technical feature is the grafted homodetic cyclopeptide and not the $\alpha\beta3$ integrin inhibitor, cyclo (RGDfK) disclosed by Liu. Thus, the Applicants respectfully submit that the alleged shared technical feature of the $\alpha\beta3$ integrin inhibitor, cyclo (RGDfK) which is allegedly anticipated by Liu is not correct. Instead, the common technical feature is the grafted homodetic cyclopeptide which is not disclosed by Liu.

In particular, the common technical feature is the grafted homodetic cyclopeptide obtained by the method defined in Claim 36, namely a grafted homodetic cyclopeptide particularly defining two faces which are both grafted and on which at least one molecule interest is grafted via an oxime bond. This is novel over the prior art and is a common technical feature of all of the claims.

As a consequence, the set of claims that include claims directed to the grafted homodetic cyclopeptide, a composition comprising the grafted homodetic cyclopeptide, a method for preparing a grafted homodetic cyclopeptide and a method for treating cancer comprising administering a therapeutically effective amount of the composition readily falls into the unity of invention inasmuch as they all have a common technical feature of which is novel over the prior art.

As a consequence, the Applicants respectfully request that both the restriction requirement and the requirement for the election of species be withdrawn and that all of the claims be examined on the merits.

Respectfully submitted,



T. Daniel Christenbury
Reg. No. 31,750
Attorney for Applicants

TDC/as
(215) 656-3381